目的:研究安子合剂对抗磷脂抗体(APA)阳性流产小鼠Toll样受体4(TLR4)/髓样分化因子88(My D88)/核因子κB(NF-κB)信号通路的影响,探讨其抗APA阳性流产作用机制。方法:将BALB/c小鼠(♀)随机分为空白对照组、模型组、阿司匹林组(阳性对照,...目的:研究安子合剂对抗磷脂抗体(APA)阳性流产小鼠Toll样受体4(TLR4)/髓样分化因子88(My D88)/核因子κB(NF-κB)信号通路的影响,探讨其抗APA阳性流产作用机制。方法:将BALB/c小鼠(♀)随机分为空白对照组、模型组、阿司匹林组(阳性对照,0.019 5 g/kg)和安子合剂低、中、高剂量组(37.7、75.4、150.8 g/kg,以生药计),每组10只。除空白对照组外,其余各组小鼠均以人β2-糖蛋白Ⅰ为诱导剂建立APA阳性流产模型。从妊娠第1天起,各给药组小鼠ig相应药物,空白对照组和模型组小鼠ig等体积生理盐水,每天1次,连续9 d。分别采用实时荧光定量聚合酶链反应法和免疫组化法测定胎盘组织TLR4、髓样分化蛋白2(MD2)、My D88、NF-κB m RNA及其蛋白表达水平。结果:与空白对照组比较,模型组小鼠胎盘组织TLR4、MD2、My D88、NF-κB m RNA及其蛋白表达水平均显著升高(P<0.01)。与模型组比较,阿司匹林组和安子合剂低、中剂量组小鼠胎盘组织TLR4、MD2、My D88 m RNA及其蛋白表达水平,安子合剂高剂量组小鼠胎盘组织TLR4蛋白表达水平,以及各给药组小鼠胎盘组织NF-κB蛋白表达水平均显著降低(P<0.05或P<0.01);安子合剂低剂量组小鼠胎盘组织TLR4、MD2 m RNA表达水平和MD2、My D88蛋白表达水平较阿司匹林组更低(P<0.05或P<0.01)。结论:安子合剂可抑制APA阳性流产小鼠TLR4/My D88/NF-κB信号通路转导,这可能是其抗APA阳性流产的作用机制之一。展开更多
目的:观察青藤碱(SN)对脂多糖(LPS)诱导的类风湿关节炎(RA)患者外周血单核细胞TLR4/My D88/NF-κB m RNA及蛋白表达的影响。方法:采用活动期RA患者外周血进行单核细胞的分离培养,并与健康志愿者做对照。分为健康对照组、RA对照组、RA+LP...目的:观察青藤碱(SN)对脂多糖(LPS)诱导的类风湿关节炎(RA)患者外周血单核细胞TLR4/My D88/NF-κB m RNA及蛋白表达的影响。方法:采用活动期RA患者外周血进行单核细胞的分离培养,并与健康志愿者做对照。分为健康对照组、RA对照组、RA+LPS组,SN低剂量组,SN高剂量组及TAK-242组进行观察。采用RT-PCR法及Western blot法检测各组TLR4、My D88及NF-κB m RNA及蛋白的表达。结果:RA对照组TLR4、My D88及NF-κB m RNA及蛋白表达均明显高于健康对照组(P<0.01);RA+LPS组均明显高于RA对照组(P<0.01);SN低剂量组、SN高剂量组均明显低于RA+LPS组(P<0.01),且SN不同剂量组之间差异有统计学意义(P<0.01)。结论:SN可有效抑制LPS诱导的单核细胞TLR4、My D88及NF-κBm RNA及蛋白的表达,其对RA的治疗作用可能与抑制TLR4/My D88/NF-κB信号通路介导的炎症反应有关。展开更多
Objective:To investigate the clinical efficacy of dexmedetomidine in the regulation of TLR4/My D88/NF-κB in the prevention of paroxysmal sympathetic over-excitation (PSH) in patients with severe head injury. Methods:...Objective:To investigate the clinical efficacy of dexmedetomidine in the regulation of TLR4/My D88/NF-κB in the prevention of paroxysmal sympathetic over-excitation (PSH) in patients with severe head injury. Methods:One hundred patients with severe head injury who were admitted to our hospital from September 2016 to May 2019 were enrolled. The randomized digital table method was divided into 50 cases in the study group and the control group. Patients in the study group were given dexmedetomidine at a dose of 1.0 μg/kg before anesthesia induction, followed by infusion at 0.4 μg / (kg·h), and the control group was injected with the same amount of normal saline. The incidence of PSH, clinical symptoms, imaging findings, mechanical ventilation time, tracheal intubation/incision duration, ICU hospitalization time, total length of hospital stay, and GCS scores three months after discharge were compared between the two groups. At the same time, the fluorescence intensity, TLR4, NF-κB expression level and tumor necrosis factor-α (TNF-α) expression levels in peripheral blood CD14+ monocytes of the two groups were detected. Results:The incidence of PSH was significantly lower in the study group than in the control group at 7 and 3 months (P<0.05). The total length of hospital stay, duration of ICU hospitalization, intraoperative tracheotomy, and mechanical ventilation time were significantly lower in the study group than in the control group. And the GCS score was higher than the control group, and the difference was statistically significant (P<0.05). In addition, the imaging results showed that there were some differences in the location of imaging lesions between the two groups. The proportion of lesions in the ventricular system and surrounding areas was higher in the control group than in the study group (P<0.05). And the T14-T3 CD14+ PBMC MyD88 fluorescence intensity, TLR4 and NK-κB positive expression rate were significantly higher than those of T0 (P<0.05), but the MyD88 fluorescence intensity, TLR4 and NK-κB positive expression rate in the study group were significantly lower than those in the control group at T1~T3 (P<0.05). The levels of serum TNF-α in T1~T3 groups were significantly higher than those in T0 (P<0.05), but the levels of serum TNF-α in T1~T3 in the study group were significantly lower than those in the control group (P< 0.05). Conclusions:Dexmedetomidine can reduce the oxidative stress response in patients with severe head injury by inhibiting TLR4/My D88/NF-κB signaling pathway, thus effectively reducing the risk of PSH and improving the prognosis of patients.展开更多
文摘目的:研究安子合剂对抗磷脂抗体(APA)阳性流产小鼠Toll样受体4(TLR4)/髓样分化因子88(My D88)/核因子κB(NF-κB)信号通路的影响,探讨其抗APA阳性流产作用机制。方法:将BALB/c小鼠(♀)随机分为空白对照组、模型组、阿司匹林组(阳性对照,0.019 5 g/kg)和安子合剂低、中、高剂量组(37.7、75.4、150.8 g/kg,以生药计),每组10只。除空白对照组外,其余各组小鼠均以人β2-糖蛋白Ⅰ为诱导剂建立APA阳性流产模型。从妊娠第1天起,各给药组小鼠ig相应药物,空白对照组和模型组小鼠ig等体积生理盐水,每天1次,连续9 d。分别采用实时荧光定量聚合酶链反应法和免疫组化法测定胎盘组织TLR4、髓样分化蛋白2(MD2)、My D88、NF-κB m RNA及其蛋白表达水平。结果:与空白对照组比较,模型组小鼠胎盘组织TLR4、MD2、My D88、NF-κB m RNA及其蛋白表达水平均显著升高(P<0.01)。与模型组比较,阿司匹林组和安子合剂低、中剂量组小鼠胎盘组织TLR4、MD2、My D88 m RNA及其蛋白表达水平,安子合剂高剂量组小鼠胎盘组织TLR4蛋白表达水平,以及各给药组小鼠胎盘组织NF-κB蛋白表达水平均显著降低(P<0.05或P<0.01);安子合剂低剂量组小鼠胎盘组织TLR4、MD2 m RNA表达水平和MD2、My D88蛋白表达水平较阿司匹林组更低(P<0.05或P<0.01)。结论:安子合剂可抑制APA阳性流产小鼠TLR4/My D88/NF-κB信号通路转导,这可能是其抗APA阳性流产的作用机制之一。
文摘目的:观察青藤碱(SN)对脂多糖(LPS)诱导的类风湿关节炎(RA)患者外周血单核细胞TLR4/My D88/NF-κB m RNA及蛋白表达的影响。方法:采用活动期RA患者外周血进行单核细胞的分离培养,并与健康志愿者做对照。分为健康对照组、RA对照组、RA+LPS组,SN低剂量组,SN高剂量组及TAK-242组进行观察。采用RT-PCR法及Western blot法检测各组TLR4、My D88及NF-κB m RNA及蛋白的表达。结果:RA对照组TLR4、My D88及NF-κB m RNA及蛋白表达均明显高于健康对照组(P<0.01);RA+LPS组均明显高于RA对照组(P<0.01);SN低剂量组、SN高剂量组均明显低于RA+LPS组(P<0.01),且SN不同剂量组之间差异有统计学意义(P<0.01)。结论:SN可有效抑制LPS诱导的单核细胞TLR4、My D88及NF-κBm RNA及蛋白的表达,其对RA的治疗作用可能与抑制TLR4/My D88/NF-κB信号通路介导的炎症反应有关。
基金Nanchong city school cooperative research project in 2018(No.18SXHZ0445).
文摘Objective:To investigate the clinical efficacy of dexmedetomidine in the regulation of TLR4/My D88/NF-κB in the prevention of paroxysmal sympathetic over-excitation (PSH) in patients with severe head injury. Methods:One hundred patients with severe head injury who were admitted to our hospital from September 2016 to May 2019 were enrolled. The randomized digital table method was divided into 50 cases in the study group and the control group. Patients in the study group were given dexmedetomidine at a dose of 1.0 μg/kg before anesthesia induction, followed by infusion at 0.4 μg / (kg·h), and the control group was injected with the same amount of normal saline. The incidence of PSH, clinical symptoms, imaging findings, mechanical ventilation time, tracheal intubation/incision duration, ICU hospitalization time, total length of hospital stay, and GCS scores three months after discharge were compared between the two groups. At the same time, the fluorescence intensity, TLR4, NF-κB expression level and tumor necrosis factor-α (TNF-α) expression levels in peripheral blood CD14+ monocytes of the two groups were detected. Results:The incidence of PSH was significantly lower in the study group than in the control group at 7 and 3 months (P<0.05). The total length of hospital stay, duration of ICU hospitalization, intraoperative tracheotomy, and mechanical ventilation time were significantly lower in the study group than in the control group. And the GCS score was higher than the control group, and the difference was statistically significant (P<0.05). In addition, the imaging results showed that there were some differences in the location of imaging lesions between the two groups. The proportion of lesions in the ventricular system and surrounding areas was higher in the control group than in the study group (P<0.05). And the T14-T3 CD14+ PBMC MyD88 fluorescence intensity, TLR4 and NK-κB positive expression rate were significantly higher than those of T0 (P<0.05), but the MyD88 fluorescence intensity, TLR4 and NK-κB positive expression rate in the study group were significantly lower than those in the control group at T1~T3 (P<0.05). The levels of serum TNF-α in T1~T3 groups were significantly higher than those in T0 (P<0.05), but the levels of serum TNF-α in T1~T3 in the study group were significantly lower than those in the control group (P< 0.05). Conclusions:Dexmedetomidine can reduce the oxidative stress response in patients with severe head injury by inhibiting TLR4/My D88/NF-κB signaling pathway, thus effectively reducing the risk of PSH and improving the prognosis of patients.
